Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

 
International Parkinson and Movement Disorder Society
Main Content

        VOLUME 28, ISSUE 3 • SEPTEMBER 2024.  Full issue »

Research priorities on the role of α-synuclein in Parkinson's disease pathogenesis

α-Synuclein – a small protein first detected in 1988 at presynaptic terminals and nuclei of neurons – is now often considered to be synonymous with Parkinson’s disease. Indeed, α-synuclein aggregation in the form of Lewy pathology is characteristic of most forms of Parkinson’s disease, including the most common idiopathic form. Yet, despite intensive investigation into α-synuclein for more than a quarter century, the precise role of this protein in the pathogenesis and progression of Parkinson’s disease remains elusive.

To guide research efforts aimed at understanding α-synuclein’s role in Parkinson’s disease, the MDS Scientific Issues Committee (2021-2023) organized a panel of experts consisting of fundamental neuroscientists and movement disorders neurologists to discuss current scientific priorities and to identify research strategies. The MDS Scientific Issues Committee leadership carefully selected the group to represent a range of scientific expertise on the topic – from protein dynamics to electrophysiology to cell biology to neuropathology – and brought them together with leading clinician-scientists in the Parkinson’s disease field.

The following six questions were raised and addressed by the panel of experts:

  1. What are the physiologic functions of α-synuclein?
  2. What are the initial triggers of α-synuclein aggregation?
  3. What determines the distribution of α-synuclein pathology?
  4. What is the relationship between α-synuclein aggregation and neuronal dysfunction?
  5. What is the role of α-synuclein propagation in the onset and progression of Parkinson’s disease?
  6. Are neurons with α-synuclein aggregates destined to die or can they be rescued from neurodegeneration?

Discussions among the expert panel occurred during eight online meetings and an in-person meeting in Los Angeles over the course of a year. The group discussions were focused, productive, and represented a significant synergy that can be generated by bringing together fundamental scientists and clinician-scientists. The discussions resulted in an article entitled “Research Priorities on the Role of α-Synuclein in Parkinson’s Disease Pathogenesis” in Movement Disorders (DOI: 10.1002/mds.29897) with recommendations, reached by consensus, for top research priorities. These recommendations are concisely summarized in a table in the article (a simplified version is included below). The overall perspective of the panel was that developing new models and tools, as well as refining the strategy-to-target design, are critical to advance our understanding of both function and dysfunction of α-synuclein and the involvement of α-synuclein in Parkinson’s disease pathogenesis and progression.

We hope this work is not only instrumental for individual researchers by guiding their future research directions, but also influences further progress among broader Parkinson’s disease research endeavors.

Top recommended research priorities:

  • Applying physiological systems/models to characterize αSyn function at endogenous levels in native environment and non-diseased state 
  • Determining the impact of disease-associated mutations on αSyn function and fibril structure 
  • Conducting systematic analyses of αSyn regulation and the role of αSyn levels 
  • Considering cell-type specificity, cell compartment, and time requirements for studies of triggering mechanisms of αSyn aggregation 
  • Developing cell and animal models that recapitulate the different stages of αSyn aggregation 
  • Developing de novo animal models of αSyn aggregation 
  • Designing multiple target studies of primary mechanisms of αSyn folding/misfolding and aggregation
  • Systematically characterizing LP-vulnerable and LP-resistant neurons at the molecular and cellular levels 
  • Generating an unbiased, quantitative connectomic map of LP distribution 
  • Establishing standardized experimental approaches for evaluating αSyn spread using in vivo models 
  • Developing better tools to label αSyn in its various forms and cellular locations 
  • Analyzing cellular responses to LP in models and humans 
  • Developing reliable biomarkers to detect and quantify the presence and spread of pathogenic αSyn in patients across the disease spectrum (from premotor to advanced PD), and more sensitive and broadly based biomarkers of both neuronal dysfunction and neurodegeneration 
  • Prospectively studying the trajectory of people with “deleterious” SNCA SNPs who may have a more aggressive disease course 

Read more Moving Along:

Full issue    Archives

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice

Cookie Settings

  • Your Privacy

  • Strictly Necessary

  • Performance

  • Targeting/Advertising

Your Privacy

When you visit a website, it may collect information about your browser, your preferences, or your device to make the website work as you expect it to. This information is collected in the form of cookies. The information collected does not identify you directly, but it can give you a more personalized website experience. The following describes the different types of cookies we are using and gives you the option to not allow some types of cookies. Click on the category headings to learn more and change your default cookie settings. Please note that blocking some types of cookies may impact your website experience.

Strictly Necessary

Always Enabled

These cookies are essential in order to enable you to move around the website and use its features. Without these cookies, website services, such as remembering your shopping cart items, cannot be provided. We are unable to turn these cookies off in the system. While you may be able to set your browser to block or alert you about these cookies, some parts of the website will not function without them.

Modules:

Performance

These cookies collect anonymous information on how people use the website: website visits, traffic sources, click patterns and similar metrics. They help us understand what pages are the most popular. All of the information collected is aggregated and therefore anonymous. If you do not allow these cookies, we will not know when you have visited our website.

Modules:

Targeting/Advertising

These cookies collection information about your browsing habits in order to make advertising more relevant to you and your interests. They are set up through our advertising partners, who compile your interests and target you with relevant ads on other websites or platforms. If you do not allow these cookies, you will not experience our targeted advertising on other places throughout the web.

Modules: